As healthcare advocates who understand the serious risks, complications and side effects that can accompany the surgical intervention of skin cancer, we began a mission to provide patients and physicians with alternative cancer treatments—specifically, a non-surgical solution for basal cell carcinoma treatment and squamous cell carcinoma treatment.
We are honored to offer the SRT-100™. Inspired by the tried-and-true Superficial Radiotherapy systems that were once the proven gold standard among dermatologists and radiotherapy oncologists, our state-of-the-art system is ideal for basal cell carcinoma treatment and squamous cell carcinoma treatment.
With a compact 30”x30” footprint, the mobile unit delivers a precise and calibrated dose of SRT that penetrates only five millimeters below the skin’s surface—making it one of the safest and most effective alternative cancer treatments available. Unlike more powerful radiotherapy devices, the SRT-100™ carefully destroys malignant skin cancer cells while preserving healthy tissue.
The SRT-100™ is good news for the nearly 3.5 million Americans who are diagnosed with non-melanoma skin cancer each year. More than half of these newly diagnosed patients are over 60 and often have a higher risk for surgical complications due to diabetes, heart disease and other medical conditions.
While Mohs surgery has been the traditional choice for basal cell carcinoma treatment and squamous cell carcinoma treatment, it has several serious drawbacks. The excision of cancerous tissue along with healthy surrounding tissue leads to a painful and lengthy healing process that increases the risk for infection. Patients who undergo Mohs are also left with significant scarring.
Since nearly 80 percent of skin cancer occurs on visible areas of the face, head and neck, reconstructive plastic surgery is often required. The American Society of Plastic Surgeons reports that 87 percent of plastic surgeons in the U.S. perform cosmetic surgery on people who have had Mohs. In fact, reconstructive surgery following Mohs is the second most common procedure performed by plastic surgeons.
Keloid scars—the rubbery lesions or shiny, fibrous nodules triggered by too much collagen production and an overgrowth of scar tissue—can be painful and unsightly. Prevention is difficult due to a genetic predisposition in African American, Asian, Hispanic and skin of color individuals. While there are topical over-the-counter products for Keloid removal, they aren’t very effective. Keloid treatment often involves surgery, but there is a high risk that the incision made during the keloid removal, will become the site of a new keloid. The SRT-100™ has proven very effective in keloid treatment. A precise and targeted low dose of Superficial Radiotherapy following surgical keloid removal prevents the regrowth of a new keloid.
Non Reoccurrence Rate
No anesthesia, cutting, bleeding, stitching or pain
No downtime or lifestyle restrictions
Super cosmesis, no unsightly scarring
No need for post-treatment reconstructive surgeries